These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 20190366)

  • 21. Pharmacological topics of bone metabolism: recent advances in pharmacological management of osteoporosis.
    Suzuki A; Sekiguchi S; Asano S; Itoh M
    J Pharmacol Sci; 2008 Apr; 106(4):530-5. PubMed ID: 18431035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological diversity among drugs that inhibit bone resorption.
    Russell RG
    Curr Opin Pharmacol; 2015 Jun; 22():115-30. PubMed ID: 26048735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prediction by early change of bone metabolic markers of the efficacy of anti-osteoporotic drugs on bone mass in osteoporotic patients].
    Inaba M
    Clin Calcium; 2014 Mar; 24(3):379-84. PubMed ID: 24576934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men.
    Doran PM; Riggs BL; Atkinson EJ; Khosla S
    J Bone Miner Res; 2001 Nov; 16(11):2118-25. PubMed ID: 11697809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients.
    Małyszko J; Małyszko JS; Pawlak K; Wołczyński S; Myśliwiec M
    Adv Med Sci; 2006; 51():69-72. PubMed ID: 17357281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
    Bachmann G; Kriegman A; Gonçalves J; Kianifard F; Warren M; Simon JA
    Menopause; 2011 Aug; 18(8):851-6. PubMed ID: 21796066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Determinants of bone quality and strength independent of bone remodeling].
    Saito M; Marumo K
    Clin Calcium; 2016 Jan; 26(1):29-41. PubMed ID: 26728528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis.
    Sato Y; Tando T; Morita M; Miyamoto K; Kobayashi T; Watanabe R; Oike T; Matsumoto M; Nakamura M; Miyamoto T
    Biochem Biophys Res Commun; 2017 Jan; 482(4):1430-1436. PubMed ID: 27974229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Skeletal effects of selective oestrogen receptor modulators (SERMs).
    Díez JL
    Hum Reprod Update; 2000; 6(3):255-8. PubMed ID: 10874570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Management of osteoporosis by using biochemical markers for bone turnover].
    Mizunuma H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():227-30. PubMed ID: 18159710
    [No Abstract]   [Full Text] [Related]  

  • 31. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
    Ohta H
    Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Raloxifene: a new choice for treating and preventing osteoporosis.
    Licata AA; Ciaccia AV; Wong M; Draper MW
    Cleve Clin J Med; 2000 Apr; 67(4):273-80. PubMed ID: 10780099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Molecular mechanism of tissue-specific actions of SERM].
    Kato S
    Clin Calcium; 2006 Sep; 16(9):1469-74. PubMed ID: 16951470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [TARTRAT-RESISTANT ACID PHOSPHATASE AS BONE'S RESORBTION MARKER IN PATIENTS WITH BONE METASTASES].
    Dedkov AG; Boychuk SI; Stakhovsky EA; Kukushkina MN; Kovalchuk PA
    Lik Sprava; 2015; (5-6):104-9. PubMed ID: 27089726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Current topics in drug therapy aiming at bone resorption].
    Yasui T; Tanaka S
    Clin Calcium; 2006 Sep; 16(9):1475-79. PubMed ID: 16951471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Tartrate resistant acid phosphatase--TRACP-5b as a modern bone resorption marker].
    Nowak Z; Konieczna M; Saracyn M; Wańkowicz Z
    Pol Merkur Lekarski; 2008 Apr; 24(142):351-4. PubMed ID: 18634372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of raloxifene as a SERM on bone metabolism].
    Ohta H
    Nihon Rinsho; 2006 Apr; 64 Suppl 4():411-8. PubMed ID: 16689343
    [No Abstract]   [Full Text] [Related]  

  • 38. [Assessment of bone quality. Effects of bisphosphonates, raloxifene, alfacalcidol, and menatetrenone on bone quality: collagen cross-links, mineralization, and microdamage].
    Saito M
    Clin Calcium; 2008 Mar; 18(3):364-72. PubMed ID: 18310825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective estrogen receptor modulators: A possible new treatment of osteoporosis in males.
    Kastelan D; Giljevic Z; Kraljevic I; Korsic M
    Med Hypotheses; 2006; 67(5):1052-3. PubMed ID: 16790322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of SERMs on bone health. Changes in bone metabolism in cases of gender identity disorder].
    Miyajima T
    Clin Calcium; 2010 Mar; 20(3):380-7. PubMed ID: 20190368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.